Skip to Accessibility Menu Skip to Login Skip to Content Skip to Footer
A silhouette of a man stands behind a graph showing rising testosterone levels.

What is Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)?

Editorial Team's avatar image

By Editorial Team

1 min read

Many men that are diagnosed with early-stage prostate cancer will achieve no evidence of disease (NED) after getting treatment. There is the possibility for prostate cancer to progress after getting treatment, including having surgery or having radiation treatment.

Progressing prostate cancer

Prostate cancer that is no longer stopped by low testosterone levels is called castration-resistant. Castration-resistant prostate cancer is a type of prostate cancer in which the patient's PSA level is rising and the cancer has spread to other areas of the body. If the cancer has not spread to other parts of the body, it is called non-metastatic castration-resistant prostate cancer.1

By providing your email address, you are agreeing to our Privacy Policy and Terms of Use.

What is non-metastatic castration-resistant prostate cancer (nmCRPC)?

Non-metastatic castration-resistant prostate cancer (nmCRPC) is a type of prostate cancer in which:

  • The cancer has not metastasized (spread) to other areas of the body
  • The cancer is no longer responding to medical or surgical treatment that lowers testosterone (ADT) and
  • The patient is continuing to have rising PSA levels (prostate-specific antigen) even when having low testosterone levels in the blood1

Treatment options for nmCRPC

The treatment landscape for nmCRPC is evolving and the Food and Drug Administration (FDA) has approved 2 anti-androgens for nmCRPC, Erleada (apalutamide) and Xtandi (enzalutamide), both for delaying metastases. These novel androgen-modulating drugs provide promise for prolonging progression-free survival (PFS) for patients.2

Join the conversation

Please read our rules before commenting.